Evidence map›Paper›PMID 38178666›Full record

ReviewInfectious disorders drug targets2024

Rapidly Evolving SARS-CoV-2: A Brief Review Regarding the Variants and their Effects on Vaccine Efficacies.

Shahid Nawaz, Sara Janiad, Aiman Fatima, Maira Saleem, Urooj Fatima, Asad Ali

Abstract readReview
PubMed Publisher
In one paragraph

Review in Infectious disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. SARS-CoV-2 mutant spectrum complexity is an epidemiologically evolvable trait.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shahid NawazInstitute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
Sara JaniadDepartment of Microbiology and Molecular Genetics, The Women University Multan, Multan, Pakistan.
Aiman FatimaInstitute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
Maira SaleemInstitute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
Urooj FatimaDepartment of Microbiology and Molecular Genetics, The Women University Multan, Multan, Pakistan.
Asad AliInstitute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
University of the Punjab · PKThe Women University Multan · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the commencement of Corona Virus Disease 2019 (COVID-19) pandemic, which has resulted in millions of mortalities globally, the efforts to minimize the damages have equally been up to the task. One of those efforts includes the mass vaccine development initiative targeting the deadly Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). So far, vaccines have tremendously decreased the rate of transmission and infection in most parts of the world. However, the repeated resurgence of different types of mutated versions of the virus, also known as variants, has somehow created uncertainties about the efficacies of different types of vaccines. This review discusses some of the interesting SARS-CoV-2 features, including general structure, genomics, and mechanisms of variants development and their consequent immune escape. This review also focuses very briefly on antigenic drift, shift, and vaccine-developing platforms.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Vaccine EfficacyHumansMutationVaccine DevelopmentCOVID-19 VaccinesAntigenicityCOVID-19SARS-CoV-2spike proteinvaccinesvariants.

Identifiers

PMID38178666
OpenAlexW4390609355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.